Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) + fulvestrant (F) in patients (pts) with PIK3CA-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2- LA/MBC) Meeting Abstract
| Authors: | Turner, N.; Jhaveri, K.; Kalinsky, K.; Loibl, S.; Loi, S.; Im, S. A.; Saura, C.; Schmid, P.; Schutzman, J. L.; Stout, T.; Lei, G.; Hutchinson, K. E.; Thanopoulou, E.; Juric, D. |
| Abstract Title: | Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) + fulvestrant (F) in patients (pts) with PIK3CA-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2- LA/MBC) |
| Meeting Title: | ESMO Virtual Congress 2020 |
| Journal Title: | Annals of Oncology |
| Volume: | 31 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2020 Sep 19-21/Oct 16-18 |
| Meeting Location: | Virtual |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2020-09-01 |
| Start Page: | S391 |
| End Page: | S392 |
| Language: | English |
| ACCESSION: | WOS:000573469100355 |
| DOI: | 10.1016/j.annonc.2020.08.457 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 355TiP -- Source: Wos |
